Pamela Rose-Deandrea
Acute Care · Hackensack, NJNPI 1114177045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 40.6% of the total. Reporting peaked in 2023 at $1,259 and has fallen 79.2% since, to $262 in 2025. Among acute care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$323
- Biohaven Pharmaceutical Holding Company Ltd.$277
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- Otsuka America Pharmaceutical, Inc.$163
- SK Life Science, Inc.$159
- plus $498 from 13 others
What the payments were for
- Food & beverage$2,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$723
- NURTEC ODT$244
- XCOPRI$126
- INGREZZA$122
- ABILIFY ASIMTUFII$118
- ABILIFY MAINTENA$118
How this compares
$2,703 in reported general payments places this provider in the 90th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $25,622 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $2,916 |
| Atorvastatin Calcium | 86 | $2,142 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $1,605 |
| LantusInsulin Glargine,hum.Rec.Anlog | 16 | $1,170 |
| Levothyroxine Sodium | 65 | $1,055 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 31 | $926 |
| Metformin Hcl | 82 | $912 |
| Divalproex Sodium | 17 | $778 |
| Memantine Hcl | 13 | $774 |
| FenofibrateFenofibrate Nanocrystallized | 21 | $760 |
| Tramadol Hcl | 14 | $596 |
| Nystatin | 12 | $473 |
| Ondansetron Hcl | 17 | $440 |
| Quetiapine Fumarate | 15 | $426 |
Paid to pharmacies, not to this prescriber.
Other acute care in Hackensack
- Gabriella MagarelliHackensack$44K
- Maria Tedi CoronelHackensack$19K
- Patricia WaltersHackensack$10K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Hanane ChaibainouWestampton$16K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.